Drugs / Eloctate ITI
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT04303572 Background | Nov 2021 → Jun 2022 | severe hemophilia A | Margaret Ragni | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Eloctate ITI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04303572 ↗ |
| Modality | Protein / enzyme biologic | “This is a factor VIII-Fc infusion protein.” NCT04303572 ↗ |
| Route | Intravenous | “Eloctate 100 IU/kg every other day by intravenous infusion” NCT04303572 ↗ |